CN114898808A - Method and system for predicting sensitivity of Klebsiella pneumoniae to cefepime - Google Patents
Method and system for predicting sensitivity of Klebsiella pneumoniae to cefepime Download PDFInfo
- Publication number
- CN114898808A CN114898808A CN202210823538.7A CN202210823538A CN114898808A CN 114898808 A CN114898808 A CN 114898808A CN 202210823538 A CN202210823538 A CN 202210823538A CN 114898808 A CN114898808 A CN 114898808A
- Authority
- CN
- China
- Prior art keywords
- klebsiella pneumoniae
- gene
- predicted
- copy number
- cefepime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/20—Sequence assembly
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/50—Molecular design, e.g. of drugs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Health & Medical Sciences (AREA)
- Theoretical Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Computing Systems (AREA)
- Zoology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Wood Science & Technology (AREA)
- Databases & Information Systems (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioethics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Software Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a method and a system for predicting sensitivity of klebsiella pneumoniae to cefepime, and belongs to the technical field of molecular biology. The method is characterized in that: the value of h (x) is calculated according to the following formula I: formula I:
Description
Technical Field
The invention belongs to the technical field of molecular biology, and particularly relates to a method and a system for predicting sensitivity of Klebsiella pneumoniae to cefepime.
Background
There are mainly 4 mechanisms for microbial resistance to antibiotics: (1) antibiotic efflux; (2) degradation or modification of antibiotics; (3) protection of antibiotic action sites; (4) drug-resistant bacteria reduce the ability of cells to permeate antibiotics. Numerous studies have shown that the use of antibiotics and the spread of antibiotic resistance show a good correlation, and that the resistance of environmental microorganisms can spread to human pathogenic bacteria through gene lateral transfer, which may eventually lead to outbreaks of super bacteria, directly affecting human health.
Microbial samples come from a variety of sources. Intestinal samples include feces, mucous membranes, etc., fluid samples include urine, blood, cerebral medullary fluid, saliva, sputum, alveolar lavage fluid, amniotic fluid, etc., swab samples include oral cavity, genital tract, skin, etc., and others include tissues, liver, eyes, placenta, etc.
Klebsiella pneumoniae (Klebsiella pneumoniae, abbreviated as pneumoconiae) is a common gram-negative bacterium in clinic, and can cause community and hospital acquired infection as an important pathogenic bacterium in enterobacteriaceae, resulting in various infectious diseases such as pneumonia, liver abscess, urinary system infection and bloodstream infection. Lung grams comprise 3 subspecies: namely, subspecies pneumoniae, subspecies rhinorrhea and subspecies rhinoscleroma, of which the subspecies pneumoniae is the most common, also known as Friedlander bacillus. Scholars in the middle of the 80's of the 20 th century found that pneumocandins evolved gradually and formed 2 distinct clonal groups, one exhibiting multiple drug resistance, even carbapenem resistance, the so-called classical pneumocandins (classic Klebsiella pneumoniae, cKP); while the other exhibits high virulence, the so-called high virulence pneumoconiae (hvKP).
Cefepime (cefepime) belongs to the fourth generation cephalosporins. The antibacterial spectrum of the strain is further expanded, and the strain has stronger antibacterial activity on various gram positive and negative bacteria including enterobacter, pseudomonas aeruginosa, other non-zymogenic bacilli, haemophilus, staphylococcus and the like. Can be used for treating various infections caused by sensitive bacteria, and is mainly used for treating respiratory tract infection caused by staphylococcus aureus, enterobacter, pseudomonas aeruginosa and the like.
The drug resistance rate of klebsiella pneumoniae to penicillins, cephalosporins, aminoglycosides and quinolones is increased year by year, especially to cefotaxime and cefepime.
At present, the conventional methods for detecting drug resistance of klebsiella pneumoniae strains include: the method of broth dilution in minute quantities, which is well known in the art, is combined with the "standards for the execution of NCCLS antibiotic susceptibility tests" for drug susceptibility testing, or is performed mainly based on the metabolic characteristics of bacteria to biochemical substances, such as the paper diffusion method (which is more common in routine laboratories) and the antibiotic dilution method (MIC method). The use of automated drug susceptibility and identification systems is a development direction for clinical microbiology tests, including in vitro drug susceptibility tests. Most typically, the VITEK-2 compact full-automatic bacteria identification/drug sensitive system. The system evaluates the drug sensitivity condition of the Klebsiella pneumoniae strain through the test result of detecting the extended-spectrum beta-lactamase by a VITEK-2 compact AST-GN13 drug sensitivity strip. Taking a blood culture specimen as an example, the using method of the system comprises the steps of collecting venous blood under the aseptic operation condition, injecting the venous blood into a corresponding blood culture bottle, placing the blood culture bottle in a blood culture instrument for continuous oscillation culture and monitoring, immediately transferring a blood plate when the instrument alarms that a positive bottle exists, placing the blood plate at 35 ℃ for culture for 24-48 h, carrying out smear dyeing classification after bacterial growth, and then adopting a VITEK-2 compact full-automatic microbial analyzer to continuously identify and carry out drug sensitivity test detection. The system can simultaneously complete bacteria identification and drug sensitivity test, and has the advantages of simple and rapid method, wide identification range, small artificial influence and high reliability. When the VITEK-2 compact system is used for identifying bacteria, when bacterial colony is impure or the culture time of the bacteria is insufficient during identification, the identification result is greatly different from the bacterial colony shape or the shape under a bacterial microscope, and the identification result needs to be rechecked when the biochemical reaction result in the identification system is not consistent and the like. In addition, in the case of freeze-dried strains such as the interstitial evaluation of the operating chamber, resuscitation passage is important, and accurate identification results can be obtained only by the VITEK-2 compact system after the biological characteristics of the strains are stabilized. In recent years, a series of rapid drug resistance detection technologies, including PCR technology, DNA probe hybridization and biochip technology, have been developed, and such methods are rapid and accurate, and can obtain detection results within several hours. The detection of the bacterial drug resistance by the molecular biology technology mainly adopts nucleic acid probes, multiplex PCR and fluorescent quantitative PCR detection.
Although the traditional method can meet partial clinical requirements, the traditional method has the defects of long detection time, inaccurate detection result and the like. Especially, the microorganism culture method is needed to culture the strain like a trace broth dilution method, a paper diffusion method, an antibiotic dilution method and the like, and the operation is complicated, time and labor are wasted, and the efficiency is low. Although the VITEK-2 compact full-automatic bacteria identification/drug sensitivity system is simple, convenient and quick, the accuracy of identification/drug sensitivity evaluation of the strains is influenced by the state of a sample and the culture condition of the strains, and the use cost is higher.
Therefore, there is a need in the art to develop a method and system for predicting sensitivity of klebsiella pneumoniae strain to cefepime quickly, accurately and at low cost.
Disclosure of Invention
In view of the above-mentioned shortcomings and needs of the prior art in the art, the present invention aims to provide a model and method for predicting sensitivity of klebsiella pneumoniae to cefepime.
The technical scheme of the invention is as follows:
a method for predicting the sensitivity of klebsiella pneumoniae to cefepime, which is characterized by calculating the value of h (x) according to the following formula I:
formula I:
；
wherein e is a natural constant;
c1 is the copy number of TEM-1 gene in Klebsiella pneumoniae strain to be predicted,
c2 is the copy number of KPC-1 gene in Klebsiella pneumoniae strain to be predicted,
c3 is the copy number of CTX-M-65 gene in Klebsiella pneumoniae strain to be predicted,
c4 is the copy number of the rmtB gene in the Klebsiella pneumoniae strain to be predicted,
c5 is the copy number of AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted.
In formula I, e = 2.718281828459045.
The result of the prediction of the value of h (x) is that the Klebsiella pneumoniae is resistant to cefepime and the result of the prediction of the value of h (x) is less than 0.5 is that the Klebsiella pneumoniae is sensitive to cefepime, and the result of the prediction of h (x) =0.5 is that the sensitivity of the Klebsiella pneumoniae to cefepime is mediated.
The copy number of TEM-1, KPC-1, CTX-M-65, rmtB, AAC (6') -Ib-cr6 genes in the Klebsiella pneumoniae strain to be predicted is obtained by a second generation high-throughput sequencing method.
Copy number of gene in klebsiella pneumoniae strain to be predicted = quat
；
Preferably, the genome contigs is the longest contigs fragment obtained by assembling the sequencing result by SPAdes v3.13.0 assembly software;
the depth of the genome contigs is calculated by SPAdes v3.13.0 assembly software;
the contigs depth where the gene is located refers to the sum of the depths of the genes on each contigs with the gene copy;
preferably, each contigs with a copy of the gene is annotated using blat (v.36) software and diamond (v 2.0.4.142) software after alignment of the cds and protein sequences of the gene with the CARD database;
preferably, the depth of the gene on each contigs with a copy of the gene is calculated by the SPAdes v3.13.0 assembly software.
A system for predicting the sensitivity of klebsiella pneumoniae to cefepime comprising: a calculation unit; the calculation unit includes: a computer-readable storage medium having stored thereon a computer program; wherein the computer program, when executed by the processor, implements a method for computing a value of h (x); the value h (x) is calculated according to the following formula I:
formula I:
；
wherein e is a natural constant;
c1 is the copy number of TEM-1 gene in Klebsiella pneumoniae strain to be predicted,
c2 is the copy number of KPC-1 gene in Klebsiella pneumoniae strain to be predicted,
c3 is the copy number of CTX-M-65 gene in Klebsiella pneumoniae strain to be predicted,
c4 is the copy number of the rmtB gene in the Klebsiella pneumoniae strain to be predicted,
c5 is the copy number of AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted.
The system for predicting the sensitivity of klebsiella pneumoniae to cefepime further comprises: a result output unit; the result output unit outputs a sensitive result or a drug resistance result; the sensitive result indicates that the Klebsiella pneumoniae to be predicted is sensitive to cefepime; the drug resistance result refers to the drug resistance of the Klebsiella pneumoniae to cefepime to be predicted;
h, when the value of (x) is more than 0.5, the result output unit outputs a drug resistance result R;
when the value of h (x) is less than 0.5, the result output unit outputs a sensitive result S;
h (x) when the value is equal to 0.5, the result output unit outputs an intermediary result I;
preferably, the result output unit is communicated with the computing unit through a data path;
preferably, in formula I, e = 2.718281828459045.
The h (x) value calculated by the calculating unit is transmitted to the result output unit through the data path.
The system for predicting the sensitivity of klebsiella pneumoniae to cefepime further comprises: an experiment unit and a data input unit;
the experimental unit is communicated with the data input unit through a data path; the experimental result is transmitted to the data input unit through the data path and is converted into independent variable data;
the data input unit is communicated with the computing unit through a data path; the argument data is transmitted to the calculation unit via the data path.
The independent variable data includes: c1, C2, C3, C4, C5;
preferably, the experimental results include: the copy number of the TEM-1 gene in the Klebsiella pneumoniae strain to be predicted, the copy number of the KPC-1 gene in the Klebsiella pneumoniae strain to be predicted, the copy number of the CTX-M-65 gene in the Klebsiella pneumoniae strain to be predicted, the copy number of the rmtB gene in the Klebsiella pneumoniae strain to be predicted, and the copy number of the AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted.
In one aspect of the invention, the invention provides a method for predicting the sensitivity of klebsiella pneumoniae to cefepime drugs.
According to the method, after the obtained microorganism sample is subjected to conventional treatment, necessary links such as DNA extraction and the like for sequencing can be carried out, the state of relevant characteristics of the Klebsiella pneumoniae model in the sample is obtained through bioinformatics flow analysis, and the characteristic state information is introduced into the model, so that the drug sensitivity condition of the sample can be predicted. Compared with the traditional method, the method has the advantages of simple and convenient operation, short detection time, accurate species identification and the like.
The accuracy rate obtained by predicting the training set by the classification and prediction model cannot well reflect the future performance of the prediction model, in order to effectively judge the performance of the prediction model, a group of data sets which do not participate in the establishment of the prediction model is needed, the accuracy rate of the prediction model is evaluated on the data sets, and the independent data sets are called as test sets. The model prediction effect evaluation method comprises F1-score, Precision (Precision) and Recall (Recall) and a confusion matrix. The precision ratio is the ratio of true positive examples in the positive example sample, and corresponds to the classification in the confusion matrix, and the precision ratio is TP/(TP + FP). The recall ratio is the proportion of positive examples of the prediction result in the true positive examples, and corresponds to the classification in the confusion matrix, and the recall ratio is TP/(TP + FN). F1-score reflects the robust form of the model, calculates the precision and recall and knows TP, FN and FP, and can calculate F1-score, F1-score as 2TP/(2TP + FN + FP).
The method of the invention also has the following advantages:
the accuracy of the model is evaluated by using a test set, and the average accuracy of the prediction system and the prediction method is 0.932, the average accuracy of F1-score is 0.875, and the recall score is 0.778. The method realizes rapid and accurate prediction of drug sensitivity of a sample to be tested, has important significance for early diagnosis and treatment of infection, provides an important technical means for research on drug resistance of Klebsiella pneumoniae to cefepime, and provides a new material for research on new antibacterial targets of Klebsiella pneumoniae.
Detailed Description
In order to facilitate an understanding of the present invention, the present invention will now be described more fully in the examples.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention.
The reagents used in the following examples are all commercially available unless otherwise specified.
Sources of biological material
59 samples used in the experimental examples of the present invention were pure cultures of clinical blood culture isolated Klebsiella pneumoniae, which came from Beijing cooperative Hospital of Chinese academy of medical sciences.
Group 1 examples, drug resistance prediction method of the present invention
The embodiment of the group provides a method for predicting the sensitivity of klebsiella pneumoniae to cefepime, which is characterized in that the value h (x) is calculated according to the following formula I:
formula I:
；
wherein e is a natural constant;
c1 is the copy number of TEM-1 gene in Klebsiella pneumoniae strain to be predicted,
c2 is the copy number of KPC-1 gene in Klebsiella pneumoniae strain to be predicted,
c3 is the copy number of CTX-M-65 gene in Klebsiella pneumoniae strain to be predicted,
c4 is the copy number of the rmtB gene in the Klebsiella pneumoniae strain to be predicted,
c5 is the copy number of AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted.
In the above formula I, e is a mathematical constant, which is a base number of a natural logarithm function, also called a natural constant, a natural base number, or an euler number, and is an infinite acyclic decimal number, which has a conventional technical meaning commonly understood by those skilled in the mathematical art, and its value is about: e = 2.71828182845904523536.
In some embodiments of the present invention, the value of e in formula I is 2.718281828459045.
The genes are reported in the field, and are specifically as follows:
the KPC-1 gene and TEM-1 gene are KPC-1 and TEM-1 genes described in "Novel Carbapenem-Hydrolyzing b-Lactamase, KPC-1, from aCarbapenem-Resistant string of Klebsiella pneumoniae".
The CTX-M-65 gene and rmtB gene are CTX-M-65 and rmtB genes described in "Evolution and Comparative Genomics of F33: A-: B-plasmid cloning blaCTX-M-55 or blaCTX-M-65 in Escherichia coli and Klebsiella pneumoniae Isolated from Animals, Food Products, and Humans in China".
The AAC (6') -Ib-cr6 gene is the AAC (6') -Ib-cr6 gene described in "Genomic Analysis of multidug-Resistant Hypervirolent (Hypermucovisous) Klebsiella pneumoniae strand lattice locking the Hypermucovisous Regulators (rmpA/rmpA 2)".
In some embodiments, a value of h (x) > 0.5 is predictive of cefepime resistance (R) for klebsiella pneumoniae, a value of h (x) < 0.5 is predictive of cefepime sensitivity (S) for klebsiella pneumoniae, and a value of h (x) =0.5 is predictive of intermediate cefepime sensitivity (I) for klebsiella pneumoniae.
In a specific example, the copy number of the TEM-1 gene, KPC-1 gene, CTX-M-65 gene, rmtB gene, AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted was determined by a second generation high throughput sequencing method.
In a more specific embodiment of the present invention,
QUOTE 
；
preferably, the genomic contigs is the longest contigs fragment obtained by assembling sequencing results with the SPAdes v3.13.0 assembly software;
the depth of the genome contigs is calculated by SPAdes v3.13.0 assembly software;
the contigs depth where the gene is located refers to the sum of the depths of the genes on each contigs with the gene copy;
preferably, each contigs with a copy of the gene is annotated using blat (v.36) software and diamond (v 2.0.4.142) software after alignment of the cds and protein sequences of the gene with the CARD database;
preferably, the depth of the gene on each contigs with a copy of the gene is calculated by the SPAdes v3.13.0 assembly software.
The second generation high throughput sequencing method has the meaning of conventional techniques well known to those skilled in the art, and the use of the second generation high throughput sequencing method to obtain gene copy number is a conventional technique well known to those skilled in the art.
In some specific embodiments, the specific method of gene copy number calculation is as follows:
strains were sequenced using a second generation high throughput sequencing method. The average sequencing depth was about 150X, and the approximate sequencing amount for Klebsiella pneumoniae was about 1G. The depth of contigs obtained by calculation in the assembly process by using SPAdes v3.13.0 assembly software is taken as a standard, the longest contigs fragment is defined as a genome fragment, gene prediction is carried out on the contigs by using prokka software (1.14.6) to obtain all genes cds and protein sequences on the contigs, the cd and protein sequences are compared by using blat (v.36) software and diamond (v 2.0.4.142) software respectively to carry out CARD database, the sequence with the similarity degree of more than 90 percent is a positive sequence, and the annotation result of all drug-resistant genes is obtained. The copy number of all genes on contigs was calculated according to formula II as follows:
formula II:
if a gene has two or more genomic copies on different contigs or on the same contigs, the final gene copy number is equal to the sum of all calculated copy numbers for that gene. An example of a calculation method is as follows:
assuming that the KPC-1 gene has only one copy of all contigs, the copy number of the KPC-1 gene is:
assuming that the KPC-1 gene has 2 copies on one contigs and no copies on the other contigs, the copy number of the KPC-1 gene is:
assuming that the KPC-1 gene has 1 copy on one contig1, contig2, and no copies on the other contigs, the copy number of the KPC-1 gene is:
group 2 example, drug resistance prediction System of the present invention
The present group of embodiments provides a system for predicting the sensitivity of klebsiella pneumoniae to cefepime. All embodiments of this group share the following common features: the system for predicting the sensitivity of klebsiella pneumoniae to cefepime comprises the following components: a calculation unit; the calculation unit includes: a computer-readable storage medium having stored thereon a computer program; wherein the computer program, when executed by the processor, implements a method for computing a value of h (x); the value h (x) is calculated according to the following formula I:
formula I:
；
wherein e is a mathematical constant, is a base of a natural logarithm function, also called a natural constant, a natural base, or an euler number, and is an infinite acyclic fractional number, and the value is about:
e = 2.71828182845904523536...
in formula I, e takes the value of 2.718281828459045.
C1 is the copy number of TEM-1 gene in Klebsiella pneumoniae strain to be predicted,
c2 is the copy number of KPC-1 gene in Klebsiella pneumoniae strain to be predicted,
c3 is the copy number of CTX-M-65 gene in Klebsiella pneumoniae strain to be predicted,
c4 is the copy number of the rmtB gene in the Klebsiella pneumoniae strain to be predicted,
c5 is the copy number of AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted.
In a further embodiment, the system for predicting sensitivity of klebsiella pneumoniae to cefepime further comprises: a result output unit; the result output unit outputs a sensitive result or a drug resistance result; the sensitive result indicates that the Klebsiella pneumoniae to be predicted is sensitive to cefepime; the drug resistance result refers to the drug resistance of the Klebsiella pneumoniae to cefepime to be predicted;
h, when the value of (x) is more than 0.5, the result output unit outputs a drug resistance result R;
when the value of h (x) is less than 0.5, the result output unit outputs a sensitive result S;
h (x) is equal to 0.5, the result output unit outputs the intermediate result I.
Preferably, the result output unit is communicated with the calculation unit through a data path;
preferably, the value of h (x) calculated by the calculating unit is transmitted to the result output unit through the data path.
In a further embodiment, the system for predicting sensitivity of klebsiella pneumoniae to cefepime further comprises: an experiment unit and a data input unit;
the experimental unit is communicated with the data input unit through a data path; the experimental result is transmitted to the data input unit through the data path and is converted into independent variable data;
the data input unit is communicated with the computing unit through a data path; the independent variable data is transmitted to the computing unit through a data path;
preferably, the independent variable data includes: c1, C2, C3, C4, C5;
preferably, the experimental results include: the copy numbers of the TEM-1 gene, the KPC-1 gene, the CTX-M-65 gene, the rmtB gene and the AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted respectively.
Experimental example, Performance evaluation of prediction System and prediction method of the present invention
The prediction system of the present invention was evaluated using 59 clinical specimens, and the broth microdilution classification results and model prediction results of the 59 clinical specimens are shown in table 1 below. In the following table, S represents sensitivity, and R represents drug resistance.
The test result data generates the confusion matrix as shown in table 2 below:
let TP (true Positive) denote the number of true positive cases, FP (false positive) denote the number of false positive cases, FN (false negative) denote the number of false negative cases, and TN (true negative) denote the number of true negative cases. Precision (precision) refers to the proportion of positive samples in positive examples that are determined by the classifier. Recall refers to the proportion of total positive examples that are predicted to be positive examples. Accuracy (accuracy) refers to the specific gravity that the classifier judges correctly for the entire sample. F1-score is the harmonic mean of precision and recall, with a maximum of 1 and a minimum of 0. The calculation results of each index are as follows:
the above-mentioned embodiments only express the embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. A method for predicting the sensitivity of klebsiella pneumoniae to cefepime, which is characterized by calculating the value of h (x) according to the following formula I:
formula I:
；
wherein e is a natural constant;
c1 is the copy number of TEM-1 gene in Klebsiella pneumoniae strain to be predicted,
c2 is the copy number of KPC-1 gene in Klebsiella pneumoniae strain to be predicted,
c3 is the copy number of CTX-M-65 gene in Klebsiella pneumoniae strain to be predicted,
c4 is the copy number of the rmtB gene in the Klebsiella pneumoniae strain to be predicted,
c5 is the copy number of AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted.
2. The method of claim 1, wherein in formula I, e =2.718281828459045, the sensitivity of Klebsiella pneumoniae to cefepime is predicted.
3. The method according to claim 1, wherein the prediction result of h (x) value > 0.5 is that the Klebsiella pneumoniae is resistant to cefepime, the prediction result of h (x) value < 0.5 is that the Klebsiella pneumoniae is sensitive to cefepime, and the prediction result of h (x) =0.5 is that the Klebsiella pneumoniae is sensitive to cefepime.
4. The method for predicting the sensitivity of Klebsiella pneumoniae to cefepime according to claim 1, wherein the copy number of TEM-1, KPC-1, CTX-M-65, rmtB, AAC (6') -Ib-cr6 genes in the Klebsiella pneumoniae strain to be predicted is determined by a second generation high throughput sequencing method.
5. The method for predicting sensitivity of Klebsiella pneumoniae to cefepime according to claim 4, wherein the copy number of the gene in the Klebsiella pneumoniae strain to be predicted = i
；
And/or the genome contigs is the longest contigs fragment obtained by assembling the sequencing result by SPAdes v3.13.0 assembling software;
the depth of the genome contigs is calculated by SPAdes v3.13.0 assembly software;
the contigs depth where the gene is located refers to the sum of the depths of the genes on each contigs with the gene copy;
and/or, each contigs with the gene copy is obtained by comparing the cds and protein sequences of the gene with the CARD database and annotating by using blat (v.36) software and diamond (v 2.0.4.142) software;
and/or the depth of the gene on each contigs with a copy of the gene is calculated by the SPAdes v3.13.0 assembly software.
6. A system for predicting the sensitivity of klebsiella pneumoniae to cefepime comprising: a calculation unit; the calculation unit includes: a computer-readable storage medium having stored thereon a computer program; wherein the computer program, when executed by the processor, implements a method for computing a value of h (x); the value h (x) is calculated according to the following formula I:
formula I:
；
wherein e is a natural constant;
c1 is the copy number of TEM-1 gene in Klebsiella pneumoniae strain to be predicted,
c2 is the copy number of KPC-1 gene in Klebsiella pneumoniae strain to be predicted,
c3 is the copy number of CTX-M-65 gene in Klebsiella pneumoniae strain to be predicted,
c4 is the copy number of the rmtB gene in the Klebsiella pneumoniae strain to be predicted,
c5 is the copy number of AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted.
7. The system for predicting sensitivity of Klebsiella pneumoniae to cefepime according to claim 6, further comprising: a result output unit; the result output unit outputs a sensitive result or a drug resistance result; the sensitive result indicates that the Klebsiella pneumoniae to be predicted is sensitive to cefepime; the drug resistance result refers to the drug resistance of the Klebsiella pneumoniae to cefepime to be predicted;
h, when the value of (x) is more than 0.5, the result output unit outputs a drug resistance result R;
when the value of h (x) is less than 0.5, the result output unit outputs a sensitive result S;
h (x) when the value is equal to 0.5, the result output unit outputs an intermediary result I;
and/or the result output unit is communicated with the calculation unit through a data path;
and/or, in formula I, e = 2.718281828459045.
8. The system according to claim 7, wherein the value of h (x) calculated by the calculating unit is transmitted to the result output unit via the data path.
9. The system for predicting sensitivity of klebsiella pneumoniae to cefepime according to any one of claims 6-8, further comprising: an experiment unit and a data input unit;
the experimental unit is communicated with the data input unit through a data path; the experimental result is transmitted to the data input unit through the data path and is converted into independent variable data;
the data input unit is communicated with the computing unit through a data path; the argument data is transmitted to the calculation unit via the data path.
10. The system for predicting susceptibility of klebsiella pneumoniae to cefepime according to claim 9, wherein the independent variable data comprise: c1, C2, C3, C4, C5;
and/or, the experimental results include: the copy number of the TEM-1 gene in the Klebsiella pneumoniae strain to be predicted, the copy number of the KPC-1 gene in the Klebsiella pneumoniae strain to be predicted, the copy number of the CTX-M-65 gene in the Klebsiella pneumoniae strain to be predicted, the copy number of the rmtB gene in the Klebsiella pneumoniae strain to be predicted, and the copy number of the AAC (6') -Ib-cr6 gene in the Klebsiella pneumoniae strain to be predicted.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210823538.7A CN114898808B (en) | 2022-07-14 | 2022-07-14 | Method and system for predicting sensitivity of Klebsiella pneumoniae to cefepime |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210823538.7A CN114898808B (en) | 2022-07-14 | 2022-07-14 | Method and system for predicting sensitivity of Klebsiella pneumoniae to cefepime |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114898808A true CN114898808A (en) | 2022-08-12 |
| CN114898808B CN114898808B (en) | 2022-09-16 |
Family
ID=82729971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210823538.7A Active CN114898808B (en) | 2022-07-14 | 2022-07-14 | Method and system for predicting sensitivity of Klebsiella pneumoniae to cefepime |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114898808B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115798577A (en) * | 2023-02-06 | 2023-03-14 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of Klebsiella to levofloxacin |
| CN115798575A (en) * | 2023-02-06 | 2023-03-14 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of Klebsiella to ceftazidime |
| CN115862730A (en) * | 2023-02-06 | 2023-03-28 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of Klebsiella to cefoxitin |
| CN115881213A (en) * | 2023-02-06 | 2023-03-31 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of klebsiella to piperacillin-tazobactam |
| CN115938478A (en) * | 2023-02-06 | 2023-04-07 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of Klebsiella to amikacin |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101519688A (en) * | 2008-09-28 | 2009-09-02 | 钟建平 | Detection method for drug resistant genes of Klebsiella pneumoniae against belta-lactamase |
| CN103130881A (en) * | 2013-02-06 | 2013-06-05 | 台州市立医院 | Novel drug resistant gene of Klebsiella pneumoniae |
| CN107475422A (en) * | 2017-09-08 | 2017-12-15 | 中国人民解放军总医院 | Kit for pneumonia pathogenic bacteria drug resistant gene quick detection |
| KR102193101B1 (en) * | 2019-07-05 | 2020-12-21 | 연세대학교 산학협력단 | Novel bacteriophage specific for Klebsiella genus bacteria resistant to antibiotics |
-
2022
- 2022-07-14 CN CN202210823538.7A patent/CN114898808B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101519688A (en) * | 2008-09-28 | 2009-09-02 | 钟建平 | Detection method for drug resistant genes of Klebsiella pneumoniae against belta-lactamase |
| CN103130881A (en) * | 2013-02-06 | 2013-06-05 | 台州市立医院 | Novel drug resistant gene of Klebsiella pneumoniae |
| CN107475422A (en) * | 2017-09-08 | 2017-12-15 | 中国人民解放军总医院 | Kit for pneumonia pathogenic bacteria drug resistant gene quick detection |
| KR102193101B1 (en) * | 2019-07-05 | 2020-12-21 | 연세대학교 산학협력단 | Novel bacteriophage specific for Klebsiella genus bacteria resistant to antibiotics |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115798577A (en) * | 2023-02-06 | 2023-03-14 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of Klebsiella to levofloxacin |
| CN115798575A (en) * | 2023-02-06 | 2023-03-14 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of Klebsiella to ceftazidime |
| CN115862730A (en) * | 2023-02-06 | 2023-03-28 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of Klebsiella to cefoxitin |
| CN115881213A (en) * | 2023-02-06 | 2023-03-31 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of klebsiella to piperacillin-tazobactam |
| CN115938478A (en) * | 2023-02-06 | 2023-04-07 | 中国医学科学院北京协和医院 | System and method for predicting sensitivity of Klebsiella to amikacin |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114898808B (en) | 2022-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114898808B (en) | Method and system for predicting sensitivity of Klebsiella pneumoniae to cefepime | |
| De Goffau et al. | Human placenta has no microbiome but can contain potential pathogens | |
| Hauser et al. | Sinus culture poorly predicts resident microbiota | |
| CN114898800B (en) | Method and system for predicting sensitivity of klebsiella pneumoniae to ceftriaxone | |
| Horiba et al. | Next-generation sequencing to detect pathogens in pediatric febrile neutropenia: a single-center retrospective study of 112 cases | |
| Jordan | Molecular diagnosis of neonatal sepsis | |
| Lee et al. | Comparative of clinical performance between next-generation sequencing and standard blood culture diagnostic method in patients suffering from sepsis | |
| CN115798577B (en) | System and method for predicting sensitivity of Klebsiella to levofloxacin | |
| CN115798575B (en) | System and method for predicting sensitivity of klebsiella to ceftazidime | |
| CN115798574B (en) | System and method for predicting sensitivity of klebsiella to meropenem | |
| CN115938478B (en) | System and method for predicting sensitivity of Klebsiella to amikacin | |
| Liu et al. | Clinical application value of metagenomic next-generation sequencing in the diagnosis of central nervous system infections | |
| CN115862730B (en) | System and method for predicting sensitivity of Klebsiella to cefoxitin | |
| CN115881213B (en) | System and method for predicting sensitivity of klebsiella to piperacillin-tazobactam | |
| CN115798576B (en) | System and method for predicting sensitivity of Klebsiella to imipenem | |
| Zhong et al. | Metagenomic next-generation sequencing for rapid detection of pulmonary infection in patients with acquired immunodeficiency syndrome | |
| CN116072241A (en) | System and method for predicting sensitivity of klebsiella pneumoniae to ciprofloxacin | |
| CN114196768B (en) | Specific molecular target for identifying pseudomonas aeruginosa serogroup and rapid detection method thereof | |
| CN110184368B (en) | Specific primer for detecting towneri acinetobacter, method and application | |
| Xu et al. | Application of Next Generation Sequencing in identifying different pathogens | |
| CN116110511A (en) | System and method for predicting sensitivity of klebsiella pneumoniae to ertapenem | |
| Yu et al. | rRNA Analysis Based on Long‐Read High‐Throughput Sequencing Reveals a More Accurate Diagnostic for the Bacterial Infection of Ascites | |
| Toma et al. | Pathogen detection and characterization from throat swabs using unbiased metatranscriptomic analyses | |
| Abuhilal | Comparison between cultivation and 16s RNA sequencing based-approaches analysis for bacteria in urine and cerebrospinal fluid. | |
| WO2024026440A1 (en) | Universal microbial identification |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |